At the same time, although numerous works have analyzed the plasma levels of relaxin-2 in patients with established cardiovascular diseases (including AF), it was not analyzed the potential relationship between relaxin-2 circulating levels and different risk and/or prognostic markers related to the metabolic state and body composition8,9,17,18. This evidence concerns the gene RLN2 and atrial fibrillation.